Category: <span>Immunotherapy</span>

Category: Immunotherapy

asbestos exposure, Clinical Trials/Research/Emerging Treatments, Doctors/Specialists, Immunotherapy, mesothelioma, Mesothelioma News, Treatment

Mayo Clinic Reveals New Test for Mesothelioma

 

Mayo Clinic researchers have created a new blood test to better detect mesothelioma. This could result in earlier diagnoses. It might also lead to new options for targeted therapies. The test finds complex DNA patterns that are common in mesothelioma cells.  This new approach is more accurate than standard mesothelioma blood tests. This may also […]

The post Mayo Clinic Reveals New Test for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Chemotherapy/Chemo drugs, Clinical Trials/Research/Emerging Treatments, Immunotherapy, mesothelioma, Mesothelioma News, Treatment

FDA Approves Keytruda With Chemotherapy to Treat Mesothelioma

 

The U.S. Food and Drug Administration has approved a new first-line treatment for people with pleural mesothelioma that can’t be removed with surgery. This new approval is specifically for a Keytruda (pembrolizumab) plus pemetrexed and platinum chemotherapy combination.  The FDA’s approval follows promising results in phases 2 and 3 of the Keynote-483 trial. This clinical […]

The post FDA Approves Keytruda With Chemotherapy to Treat Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Chemotherapy/Chemo drugs, Clinical Trials/Research/Emerging Treatments, Immunotherapy, mesothelioma, Mesothelioma News, Treatment

FDA Approves Keytruda With Chemotherapy to Treat Mesothelioma

 

The U.S. Food and Drug Administration has approved a new first-line treatment for people with pleural mesothelioma that can’t be removed with surgery. This new approval is specifically for a Keytruda (pembrolizumab) plus pemetrexed and platinum chemotherapy combination.  The FDA’s approval follows promising results in phases 2 and 3 of the Keynote-483 trial. This clinical […]

The post FDA Approves Keytruda With Chemotherapy to Treat Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Clinical Trials/Research/Emerging Treatments, Immunotherapy, mesothelioma, Mesothelioma News

Phase I Trial Improves Mesothelioma Survival More Than 200%

 

Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine. The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave […]

The post Phase I Trial Improves Mesothelioma Survival More Than 200% appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Clinical Trials/Research/Emerging Treatments, Immunotherapy, mesothelioma, Mesothelioma News

Early Mesothelioma Vaccine Testing Shows Promise

 

Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine. The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave […]

The post Early Mesothelioma Vaccine Testing Shows Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Chemotherapy/Chemo drugs, Immunotherapy, mesothelioma, Mesothelioma News, Treatment

Trial Shows Keytruda With Chemotherapy Superior to Chemo Alone

 

Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with immunotherapy drugs improves patient survival more than chemotherapy alone for pleural mesothelioma. Study researchers used pembrolizumab (Keytruda) alongside platinum and pemetrexed chemotherapy. Christina S. Baik, MD, MPH, reviewed the phase 3 trial […]

The post Trial Shows Keytruda With Chemotherapy Superior to Chemo Alone appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Clinical Trials/Research/Emerging Treatments, Immunotherapy, mesothelioma, Mesothelioma News, Treatment

Mesothelioma Treatment Uses Natural Immune Cells

 

For patients with mesothelioma cancer, immunotherapy is a promising new field. Results from a recent study at Rice University in Houston are exciting. Researchers are looking at ways the natural immune system can help fight this cancer.   The study examined the therapeutic effects of interleukin 2, a form of immunotherapy for mesothelioma. IL2 is a […]

The post Mesothelioma Treatment Uses Natural Immune Cells appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Clinical Trials/Research/Emerging Treatments, Immunotherapy, Mesothelioma News, Pleural, Treatment

Study Shows Opdivo, Yervoy Effective After Mesothelioma Surgery

 

Patients with recurrent mesothelioma cancer often have few options. A new study by the Hyogo College of Medicine in Japan may have a potential answer.  This study tested the safety and efficacy of two drugs following mesothelioma surgery after cancer recurrence. The combination of immunotherapy drugs nivolumab and ipilimumab, known by the brand names Opdivo […]

The post Study Shows Opdivo, Yervoy Effective After Mesothelioma Surgery appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Clinical Trials/Research/Emerging Treatments, Immunotherapy, Mesothelioma News, Pleural

Mesothelioma Surgery With Immunotherapy Proves Effective in Study

 

An immunotherapy combination given before aggressive surgery has shown impressive effectiveness in extending survival for pleural mesothelioma patients in a recent phase II clinical trial at Baylor College of Medicine. The combination of immune checkpoint inhibitors durvalumab and tremelimumab showed an ability to effectively alter the intratumoral immune system and make surgery more effective. This […]

The post Mesothelioma Surgery With Immunotherapy Proves Effective in Study appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Immunotherapy, mesothelioma, Mesothelioma News, Treatment

UK Approves Opdivo/Yervoy Immunotherapy for Pleural Mesothelioma

 

Patients with unresectable pleural mesothelioma cancer throughout the United Kingdom will now have the immunotherapy combination of Opdivo and Yervoy as an option after its recent approval by the National Health Service for first-line treatment. The long-awaited approval comes almost two years after the U.S. Food and Drug Administration granted a similar approval of Opdivo […]

The post UK Approves Opdivo/Yervoy Immunotherapy for Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

21st Century Cures, Cancer Moonshot Initiative, chemotherapy, Clinical drug trials, Immunotherapy, Mesothelioma News, Mesothelioma Research, National Institutes of Health (NIH), Personalized Medicine Initiative, President Barack Obama, U.S. Food & Drug Administration (FDA), Vice President Joe Biden

21st Century Cures Act Will Help Fight Mesothelioma and Other Cancers

 

The 21st Century Cures Act has passed in both the House and Senate and will provide billions of dollars for researching cancer and other deadly diseases.

Atezolizumab, clinicaltrials.gov, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, FDA Modernization Act of 1997, Founder of the Bonnie J. Addario Lung Cancer Foundation Bonnie Addario, Immunotherapy, M.D., malignant pleural mesothelioma, Mesothelioma News, Non-Small Cell Lung Cancer (NSCLC), PD-L1 inhibitor, Richard Pazdur, Tecentriq, U.S. Food and Drug Administration (FDA), U.S. National Institutes of Health (NIH)

Atezolizumab Approved for Non-Small Cell Lung Cancer Patients

 

PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients.

Atezolizumab, clinicaltrials.gov, Director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, FDA Modernization Act of 1997, Founder of the Bonnie J. Addario Lung Cancer Foundation Bonnie Addario, Immunotherapy, M.D., malignant pleural mesothelioma, Mesothelioma News, Non-Small Cell Lung Cancer (NSCLC), PD-L1 inhibitor, Richard Pazdur, Tecentriq, U.S. Food and Drug Administration (FDA), U.S. National Institutes of Health (NIH)

Atezolizumab Approved for Non-Small Cell Lung Cancer Patients

 

PD-L1 inhibitor atezolizumab has been approved for use with chemotherapy-refractory metastatic Non-Small Cell Lung Cancer patients.

Amazon Web Services, Cancer Moonshot Initiative, Immunotherapy, Mesothelioma News, Microsoft, National Cancer Institute, President Barack Obama, Vice President Joe Biden

Amazon and Microsoft Helping the National Cancer Institute Moonshot Initiative

 

Amazon and Microsoft have teamed up with the National Cancer Institute to develop a repository for genome data. Read more at Mesothelioma Cancer Alliance.

Amazon Web Services, Cancer Moonshot Initiative, Immunotherapy, Mesothelioma News, Microsoft, National Cancer Institute, President Barack Obama, Vice President Joe Biden

Amazon and Microsoft Helping the National Cancer Institute Moonshot Initiative

 

Amazon and Microsoft have teamed up with the National Cancer Institute to develop a repository for genome data. Read more at Mesothelioma Cancer Alliance.